Mark D. Wittman
Research Subjects
Mark D. Wittman has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
Aixin Li
Department of Oncology Drug Discovery, Bristol-Myers Squibb Company, PO Box 4000, Princeton, NJ 08543, USA
3 shared publicationsAnn Greer
Department of Oncology Drug Discovery, Bristol-Myers Squibb Company, PO Box 4000, Princeton, NJ 08543, USA
3 shared publicationsDolatrai M. Vyas
Bristol Myers Squibb
3 shared publicationsMarco Gottardis
Department of Oncology Drug Discovery, Bristol-Myers Squibb Company, PO Box 4000, Princeton, NJ 08543, USA
3 shared publications- Upender Velaparthi
Bristol Myers Squibb
3 shared publications Balu Balasubramanian
Bristol Myers Squibb
2 shared publications
Latest Publications
- 1 February 2007
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 17 (4) , 974-977
Novel 1H-(benzimidazol-2-yl)-1H-pyridin-2-one inhibitors of insulin-like growth factor I (IGF-1R) kinase
- 1 February 2007
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 17 (4) , 974-977
Novel 1H-(benzimidazol-2-yl)-1H-pyridin-2-one inhibitors of insulin-like growth factor I (IGF-1R) kinase
- 6 August 2005
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 48 (18) , 5639-5643
Discovery of a 1H-Benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) Inhibitor of Insulin-like Growth Factor I Receptor Kinase with in Vivo Antitumor Activity
Compound 3 (BMS-536924), a novel small-molecule inhibitor of the insulin-like growth factor receptor kinase with equal potency against the insulin receptor is described. The in vitro and in vivo biological activity of this interesting compound is also reported.
- 6 August 2005
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 48 (18) , 5639-5643
Discovery of a 1H-Benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) Inhibitor of Insulin-like Growth Factor I Receptor Kinase with in Vivo Antitumor Activity
Compound 3 (BMS-536924), a novel small-molecule inhibitor of the insulin-like growth factor receptor kinase with equal potency against the insulin receptor is described. The in vitro and in vivo biological activity of this interesting compound is also reported.
- 19 March 2001
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 11 (6) , 809-810
Synthesis of metabolically blocked paclitaxel analogues
- 19 March 2001
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 11 (6) , 809-810
Synthesis of metabolically blocked paclitaxel analogues
- 1 March 2001
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 11 (6) , 811-814
Synthesis and antitumor activity of novel paclitaxel–chlorambucil hybrids
- 1 March 2001
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 11 (6) , 811-814
Synthesis and antitumor activity of novel paclitaxel–chlorambucil hybrids